Supplemental Figures
Supplemental Figure S1 . CSPG4 Supplemental Figure S2 . Effects of CSPG4 immune-targeting on OSA cell proliferation and osteosphere viability. The proliferation (a, b) and viability (c, d) of human MG-63 (a, c) and canine Penny (b, d) cells, incubated for 48 hrs with medium alone, control isotypes (25 g/ml final concentration), or anti-CSPG4 mAbs (225.28, TP32, TP49, VF20-VT87.41) was assessed by using the MTT assay. Anti-CSPG4 mAbs were mixed in a pool to a final concentration of 25 g/ml (mAbs pool) or used as single agents alone (25 g/ml final concentration). The results are expressed as the percentage (mean value + SD) of cell proliferation (a, b) and viability (c, d) in each condition respect to cells grown in the medium alone, considered as 100%. Student's t-test * P < 0.01; ** P < 0.006; *** P < 0.002; **** P < 0.0001. cell proliferation. Cell proliferation was assessed by using the MTT assay and the results are expressed as the percentage (mean value + SD) of cell viability in each condition respect to cells grown in the medium alone, considered as 100%. Cells were incubated with medium alone, Pre-Vax sera (black bars) or Post-Vax sera (blue bars) from 5 canine malignant melanoma (MM) patients after the fourth cycle of vaccination with the Hu-CSPG4 DNA vaccine in combination with 100 nM doxorubicin (DOXO). Student's t-test ** P = 0.0018.
Representative images of human MG-63 (a) and canine Penny (b)-derived osteospheres generated according the protocol described in Conti et al., 2013. 24 
